Abstract
This paper studies the direct and indirect effectiveness of Covid-19 vaccines among vaccinated healthcare workers and their unvaccinated adult household members in a mass vaccine program in Finland.
Methods We used national databases that record all polymerase chain reaction (PCR)-confirmed SARS-CoV-2 infections and mRNA-based (BNT162b2 by Pfizer-BioNTech or mRNA-1273 by Moderna) vaccine doses administered in Finland since the beginning of the epidemic. These data were merged with administrative full population datasets that include information on each person’s occupation and unique identifiers for spouses living in the same household. To estimate the direct and indirect effectiveness of mRNA-based vaccines in a household setting, we compared the cumulative incidence of PCR-confirmed SARS-CoV-2 infections between vaccinated and unvaccinated healthcare workers as well as between their unvaccinated spouses.
Findings Our estimates imply indirect effectiveness of 8.7% (95% CI: -28.9 to 35.4) two weeks and 42.9% (95% CI: 22.3 to 58.1) 10 weeks after the first dose. The effectiveness estimates for unvaccinated household members are substantial, but smaller than the direct effect and occur more gradually among unvaccinated household members than among vaccinated individuals.
Interpretation Our results suggest that mRNA-based vaccines do not only prevent SARS-CoV-2 infections among vaccinated individuals but lead to a substantial reduction in infections among unvaccinated household members. The results are consistent with the notion that mRNA-based vaccines affect susceptibility in vaccinated individuals and prevent transmission from vaccinated to unvaccinated individuals.
Competing Interest Statement
Dr. Kortelainen declares grant to his employer, but no personal support or financial relationship, from Pfizer during the conduct of the study. Other authors have no conflict of interest to declare.
Funding Statement
This research was supported by the InFLAMES and INVEST Flagship Programmes of the Academy of Finland. Dr. Kortelainen declares grant to his employer, but no personal support or financial relationship, from Pfizer during the conduct of the study. Other authors have no conflict of interest to declare.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The final data provided to the authors was de-identified. The research does not constitute human subjects research. Ethical approval was waived by the Institutional Review Board of the Finnish Institute for Health and Welfare (IRB: 00007085).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
E-mail: jussipekka.salo{at}helsinki.fi
E-mail: milla.hagg{at}helsinki.fi
E-mail: mika.kortelainen{at}utu.fi
E- mail: tuija.leino{at}thl.fi
E-mail: tanja.saxell{at}gmail.com
E-mail: markku.siikanen{at}vatt.fi
E-mail: lauri.saaksvuori{at}thl.fi
This research was supported by the InFLAMES and INVEST Flagship Programmes of the Academy of Finland. Dr. Kortelainen declares grant to his employer, but no personal support or financial relationship, from Pfizer during the conduct of the study. Other authors have no conflict of interest to declare.
Data Availability
This paper uses administrative health care and employment data maintained by the Finnish Institute for Health and Welfare and Statistics Finland. Health care data is regulated under the Act on the Secondary Use of Health and Social Data (552/2019) and can be obtained by sending a direct request to the Finnish Institute for Health and Welfare (https://thl.fi/en). The Finnish Longitudinal Employer-Employee Data (FOLK) can be obtained by sending a direct request to Statistics Finland (https://www.stat.fi). The authors are willing to assist in making data access requests.
